Skip to content

Sex-Based Differences of LA: Impact on AF Ablation.

Sex-Based Differences of Left Atrium: Impact on Atrial Fibrillation Ablation.

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07159685
Enrollment
700
Registered
2025-09-08
Start date
2026-01-01
Completion date
2026-05-30
Last updated
2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation (AF)

Brief summary

The aim of the study is to assess sex-related differences in patients who underwent a first ablation procedure for paroxysmal or persistent AF, guided by the personalized ablation strategy of the BY-LAWT protocol. Specifically, to compare anatomical characteristics, procedural parameters, and clinical outcomes between sexes.

Interventions

PROCEDUREAtrial fibrillation ablation

Atrial fibrillation ablation with RF, guided by navigation system

Sponsors

Centro Medico Teknon
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients who underwent a first ablation procedure for atrial fibrillation (paroxysmal or persistent). * Availability of an adequate pre-procedural cardiac CT scan for LAWT, LAV and inFAT analysis. * Availability of complete procedural data, including ablation index (AI) values recorded using the SmartTouch catheter (Biosense Webster). * Availability of 12-month follow-up data for efficacy and safety endpoint evaluation. * Ablation performed according to the by-LAWT protocol

Exclusion criteria

* Age \< 18 years. * Previous cardiac ablation (including AF ablation or other arrhythmias). * Incomplete data regarding procedural parameters, or follow-up. * Poor quality pre-procedural cardiac MDCT * Ablation not performed according to the BY-LAWT protocol. * Structural heart disease (e.g., dilated cardiomyopathy, valvular heart disease with surgical indication) that could substantially influence atrial dimensions or ablation response.

Design outcomes

Primary

MeasureTime frameDescription
Efficacy in AF freedomfrom the procedure to 12 months laterThe primary efficacy endpoint will be freedom from any atrial arrhythmia (AF, atrial tachycardia \[AT\], or atrial flutter \[AFL\]) at the 12-month follow-up. The following definitions apply

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026